Abstract 414P
Background
Gastrointestinal stromal tumours (GIST) are the most common mesenchymal tumours originating from the interstitial cells of Cajal and differentiates from other mesenchymal neoplasm by expression of CD117 oncogene. Most GISTs are found in the stomach followed by small bowels. Using NIH risk groups, the low risk GISTs were less frequent and the highest risk group was the commonest one. The main aim of this study was to evaluate demographic data , assess risk groups and study the clinical outcomes among GIST patients attending the Medical Oncology department , Yangon General hospital from 2015 to 2017.
Methods
Retrospective descriptive study.
Results
Among 73 patients, male: female is 2:1. The most common age group was 51-60 years. Regarding tumor site, small intestine was the most common site and the most patients were found to have tumor size between 11 to 20cm. According to TNM staging, 48% of patients were stage III. By using NIH risk stratification, it was found that 84% of patients were in high risk group. Tumour resection was performed in 77.8% and palliative resection was done in 22.2% of patients. CD117 immunostaining was performed in all 73 patients but CD117 expression was found in 69 patients. 4 patients were CD117 negative but CD34 positive. Therapy with imatinib (400–600mg) was given in 73 patients. Among them, 13 patients was occurred loss follow-up and could not assessed due to social and transportation difficulties. Three patients were expired due to disease progression. 57 patients were alive and taken imatinib up to 3 year. We initially assessed with USG and if there was suspected lesion in USG, we did further advanced imaging like CT. Among these patients who took imatinib up to 3 years, 5 patients was found to have recurrence and change to second line therapy. 52 out of 73 patients remained clinically stable and no recurrence up to 3 years. The most common side effect was generalized edema. The other side effects were whitening of skin and rash . 2 patients suffered dyspnea on exertion and assessed with echocardiogram showing reduced ejection fraction. Dose adjustment was done to these patients. 1 patient was found to have liver function derangement.Table:
414P
Tumour Profile | ||
---|---|---|
Tumour site distribution | No | Percentange |
small intestine | 37 | 51 |
Stomach | 17 | 23 |
Colon and rectum | 10 | 14 |
Extra Gastrointestinal Tract | 9 | 12 |
Tumour sizes distribution | ||
< 10 cm | 24 | 33 |
10-20 cm | 41 | 56 |
>20 cm | 8 | 11 |
Tumour stages distribution | ||
Stage I | 9 | 12 |
Stage II | 13 | 18 |
Stage III | 35 | 48 |
Stage IV | 16 | 22 |
NIH risk distribution | ||
Low | 6 | 8 |
Intermediate | 6 | 8 |
High | 61 | 84 |
Conclusions
This study showed most patients presented with larger tumour sizes, high NIH risk and small intestine. Those who received imatinib up to 3 years had low rate of recurrence and well tolerated.
Clinical trial identification
Editorial acknowledgement
It would not have been possible without the guidance of our professors and co-authors who contributed their valuable expertise to the concepts displayed in this abstract.
Legal entity responsible for the study
Medical Oncology, Yangon General Hospital.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
448P - Incidence and severity of chemotherapy induced peripheral neuropathy in geriatric population who are receiving chemotherapy
Presenter: Alekhya Mandepudi
Session: Poster display session
Resources:
Abstract
449P - Utility of screening tool for assessment of chemotherapy induced peripheral neuropathy in cancer patients
Presenter: PRUTHVI Paibhavi
Session: Poster display session
Resources:
Abstract
450P - Supportive care to control nausea and dizziness in malignant tumours: A systematic review
Presenter: Rainer Spiegel
Session: Poster display session
Resources:
Abstract
451P - The safety of ramucirumab without H1-antihistamines as a premedication in patients with solid cancers: A retrospective study
Presenter: Nobuhiro Hattori
Session: Poster display session
Resources:
Abstract
452P - Expression of erythropoietin receptor in patient with anemia related chemotherapy and its correlation with absolute reticulocyte count
Presenter: Irza Wahid
Session: Poster display session
Resources:
Abstract
453P - Body mass index did not correlate with short term overall survival in breast cancers
Presenter: Jungsun Lee
Session: Poster display session
Resources:
Abstract
454P - Predictors of severity and comparison of CTCAE V3.0 vs V4.3 in assessing chemotherapy induced extravasation injuries
Presenter: Sangana Reddy
Session: Poster display session
Resources:
Abstract
455P - Assessment of nutritional status and quality of life among cancer patients undergoing chemotherapy
Presenter: Sri Prathima
Session: Poster display session
Resources:
Abstract
456P - Use of gamma irradiated bone allografts in treatment of various bone tumours
Presenter: Anchal Mishra
Session: Poster display session
Resources:
Abstract
457P - The prevalence of vitamin D deficiency in Thai cancer patients, its dynamics and association with cancer survival
Presenter: Chavapon Ngokngarm
Session: Poster display session
Resources:
Abstract